Intensive care unit (ICU) admission for solid cancer patients treated with immune checkpoint inhibitors
Authors' conclusion
IrAEs accounted for half of ICU admissions in cancer patients receiving ICIs.
Study context
- Population
- Adults with solid tumour treated with systemic immune checkpoint inhibitors within the last 6 months requiring non-programmed ICU admission, France and Belgium (microbiologically documented sepsis excluded)eligible
- Participants
- 115 adults
- Outcome
- Imputability of irAEs in ICU admissions (WHO-UMC classification) at ICU admission and discharge
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
ICU admission "likely" associated with irAE
ICU admission "likely" associated with immune-related adverse events (irAE)
48%
n = 55
Independently associated with irAE: ECOG-PS 0 vs 2-3, OR
6.34
95% CI 2.13–18.90
Independently associated with irAE: ECOG-PS 1 vs 2-3, OR
3.66
95% CI 1.33–10.03
Independently associated with irAE: history of irAE, OR
3.28
95% CI 1.19–9.01
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Factors independently associated with irAEECOG-PS 0 vs ECOG-PS 2-3 | 6.34 (2.13–18.90) | |
| Factors independently associated with irAEECOG-PS 1 vs ECOG-PS 2-3 | 3.66 (1.33–10.03) | |
| 0.050.21520Odds ratio (log scale) |
Factors independently associated with irAE
| OR (95% CI) | ||
|---|---|---|
| History of irAE | 3.28 (1.19–9.01) | |
| 0.10.31310Odds ratio (log scale) |
Main ICU admission reasons
- Acute respiratory failure
- n = 66, 57%
- Colitis
- n = 14, 13%
- Cardiovascular disease
- n = 13, 11%
Treatment of ICU admissions likely related to irAE
- Steroids prescribed
- 41/55 (75%)
- Subsequently treated with immunosuppressants
- 3
Original publication
ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care. Published 18 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →